Oculis Holding AG (FRA:CR5) Pre-Tax Income : €-61.24 Mil (TTM As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Oculis Holding AG Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Oculis Holding AG's pretax income for the three months ended in Mar. 2024 was €-16.63 Mil. Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was €-61.24 Mil. Oculis Holding AG's pretax margin was %.

Oculis Holding AG Pre-Tax Income Historical Data

The historical data trend for Oculis Holding AG's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oculis Holding AG Pre-Tax Income Chart

Oculis Holding AG Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Pre-Tax Income

-13.69

-17.80

-39.16

-94.05

Oculis Holding AG Quarterly Data
	Dec20	Jun21	Sep21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Pre-Tax Income	Get a 7-Day Free Trial							-46.31	-13.08	-18.26	-13.27	-16.63

Competitive Comparison of Oculis Holding AG's Pre-Tax Income

For the Biotechnology subindustry, Oculis Holding AG's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oculis Holding AG's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oculis Holding AG's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Oculis Holding AG's Pre-Tax Income falls into.

Oculis Holding AG Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Oculis Holding AG's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-48.619	+	-45.551	+	-1.394	+	1.515	+	-1.4210854715202E-14
	=	-94.05

Oculis Holding AG's Pretax Income for the quarter that ended in Mar. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-15.87	+	-1.32	+	-0.042	+	0.602	+	-0.0010000000000012
	=	-16.63

Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-61.24 Mil.

Oculis Holding AG (FRA:CR5) Pre-Tax Income Explanation

Oculis Holding AG's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-16.631	/	0
	=	%

Oculis Holding AG Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Oculis Holding AG's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Oculis Holding AG (FRA:CR5) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oculis Holding AG (FRA:CR5) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

OCS:USA CR5:Germany

Address

Bahnhofstrasse 7, Zug, CHE, 6300

Website

https://www.oculis.com

Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Oculis Holding AG (FRA:CR5) Headlines

No Headlines